Equillium (NYSE:EQ) issued its quarterly earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04, Bloomberg Earnings reports.
Shares of Equillium stock opened at $3.76 on Wednesday. Equillium has a 52-week low of $3.10 and a 52-week high of $19.69. The business’s 50-day moving average price is $4.98.
A number of brokerages have recently issued reports on EQ. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Equillium in a research note on Tuesday. Zacks Investment Research upgraded shares of Equillium from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Equillium has an average rating of “Buy” and an average target price of $17.75.
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Further Reading: How to read a candlestick chart
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.